Ionis Pharmaceuticals is entering a new phase as a commercial-stage biotech, which is likely to positively impact its stock price. The anticipation of multiple product launches and a clear path to sustained positive cash flow are strong indicators of potential growth and success, making this news highly relevant and important for investors.